Fexofenadine
 |
|
 |
|
| Clinical data | |
|---|---|
| Trade names | originally Allegra, otherse |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a697035 |
| License data |
|
| Pregnancy category |
|
| Routes of administration |
by mouth |
| ATC code | |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Bioavailability | 30-41% |
| Protein binding | 60-70% |
| Metabolism | Hepatic (≤5% of dose) |
| Biological half-life | 14.4 hours |
| Excretion | Feces (~80%) and urine (~10%) as unchanged drug |
| Identifiers | |
|
|
| CAS Number | |
| PubChem CID | |
| IUPHAR/BPS | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| ChEMBL | |
| ECHA InfoCard | 100.228.648 |
| Chemical and physical data | |
| Formula | C32H39NO4 |
| Molar mass | 501.68 g/mol |
| 3D model (Jmol) | |
| Chirality | Racemic mixture |
|
|
|
|
  (what is this?)
|
|
Fexofenadine, sold under the trade name Allegra among others is an antihistamine pharmaceutical drug used in the treatment of allergy symptoms, such as hay fever, nasal congestion, and urticaria. Therapeutically, fexofenadine is a selective peripheral H1-blocker.
Fexofenadine is classified as a second-generation antihistamine because it is less able to pass the blood-brain barrier and cause sedation, compared to first-generation antihistamines. It has also been called a third-generation antihistamine, although there is some controversy associated with the use of the term.
Fexofenadine has been manufactured in generic form since 2011.
Fexofenadine is used for relief from physical symptoms associated with seasonal allergic rhinitis and for treatment of chronic urticaria. It does not cure but rather prevents the aggravation of allergic rhinitis and chronic idiopathic urticaria and reduces the severity of the symptoms associated with those conditions, providing relief from repeated sneezing, runny nose, itchy eyes or skin, and general body fatigue.
Fexofenadine has been demonstrated to be safe and effective for children ages 2–5 years old and 6–11 years old in treatment of seasonal allergic rhinitis. Recommended doses of fexofenadine in UK labeling referenced below are: For adults with seasonal allergic rhinitis (hay fever): 60 mg twice daily or 120 mg taken once a day. For children aged 6–12 years with seasonal allergic rhinitis (hay fever): 30 mg taken twice a day, in the morning and evening. For adults with chronic urticaria: 180 mg taken once a day. For adults with chronic nasal congestion.
The most common side effect demonstrated in adults was headache, but some also experienced back and muscle pain, miosis or pinpoint pupils, nausea, drowsiness, and menstrual cramps. There have also been rare reports of anxiety and insomnia. The most common side effects demonstrated during clinical trials were cough, upper respiratory tract infection, fever, and otitis media for children ages 6 to 11 and fatigue for children ages 6 months to 5 years.
...
Wikipedia